Cargando…

COVID-19 and the RAAS—a potential role for angiotensin II?

Detalles Bibliográficos
Autores principales:	Busse, Laurence W., Chow, Jonathan H., McCurdy, Michael T., Khanna, Ashish K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137402/ https://www.ncbi.nlm.nih.gov/pubmed/32264922 http://dx.doi.org/10.1186/s13054-020-02862-1

Ejemplares similares

The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature
por: Busse, Laurence W., et al.
Publicado: (2017)

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
por: Ham, Kealy R., et al.
Publicado: (2019)

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering
por: Park, Sung-Ji
Publicado: (2020)

Rethinking Vasopressor Education: The Need to Avoid Teaching the Bare Minimum
por: McCurdy, Michael T., et al.
Publicado: (2023)

Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation
por: Augustine, Robin, et al.
Publicado: (2022)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

A Shot in the Dark! RAAS Inhibitors Cause Severe COVID-19 Infection
por: Krishna, Bhuvana
Publicado: (2021)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human
por: Fagyas, Miklós, et al.
Publicado: (2014)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis
por: Pirola, Carlos J., et al.
Publicado: (2020)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition
por: Fagyas, Miklós, et al.
Publicado: (2014)

Novel Diagnostics and Therapeutics in Sepsis
por: Leong, Kieran, et al.
Publicado: (2021)

Aging- and gender-related modulation of RAAS: potential implications in COVID-19 disease
por: Monteonofrio, Laura, et al.
Publicado: (2020)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety
por: Busse, Laurence W., et al.
Publicado: (2017)

Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
por: Gnudi, Luigi, et al.
Publicado: (2010)

Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction
por: Farhadi, Susan A. S., et al.
Publicado: (2019)

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
por: Hassani, Bahareh, et al.
Publicado: (2023)

The use of angiotensin II in distributive shock
por: Chawla, Lakhmir S., et al.
Publicado: (2016)

Angiotensin II: a new therapeutic option for vasodilatory shock
por: Bussard, Rachel L, et al.
Publicado: (2018)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
por: Wachter, Rolf, et al.
Publicado: (2020)

Why the renin–angiotensin–aldosterone system (RAAS) in critically ill patients can no longer be ignored
por: Zarbock, Alexander, et al.
Publicado: (2021)

Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
Publicado: (2020)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

Reply to: RAAS inhibitors in COVID-19: not all are created equal!
por: Gonçalves, Jorge, et al.
Publicado: (2023)

Mitochondrial reactive oxygen species (ROS) as signaling molecules of intracellular pathways triggered by the cardiac renin-angiotensin II-aldosterone system (RAAS)
por: De Giusti, V. C., et al.
Publicado: (2013)

Derivation of the Immortalized Cell Line UM51-PrePodo-hTERT and Its Responsiveness to Angiotensin II and Activation of the RAAS Pathway
por: Erichsen, Lars, et al.
Publicado: (2023)

The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications
por: Papadopoulos, Konstantinos I., et al.
Publicado: (2022)

Angiotensin II, RAS Activation, and RAS Blockers in COVID-19: Unambiguous Evidence
por: Calò, Lorenzo A., et al.
Publicado: (2022)

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
por: Wieruszewski, Patrick M., et al.
Publicado: (2023)

An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers
por: Maideen, Naina Mohamed Pakkir, et al.
Publicado: (2022)

Drugs acting on the renin–angiotensin–aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies
por: Sharma, Ruchika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_51nuc57sohlsdrhtkkb8m0m6sh